Summary of IDEAYA Biosciences Update - February 23, 2026 Company Overview - **Company**: IDEAYA Biosciences (NasdaqGS:IDYA) - **Industry**: Precision medicine oncology - **Programs**: 9 clinical programs, with a focus on darovasertib in phase 3 studies for metastatic uveal melanoma [1][3] Key Points and Arguments Clinical Programs - **Darovasertib**: - Currently in two phase 3 randomized studies for first-line metastatic uveal melanoma and neoadjuvant indications [1] - Upcoming guidance on top-line results expected by the end of March 2026, focusing on median progression-free survival (PFS) as the primary endpoint [4][5] - Reported a solid 7-month PFS in previous presentations, with a follow-up of approximately 2 years [5][11] - **DLL3 Topo ADC (IDE-849)**: - Anticipated clinical data update by the end of 2026, with potential to be a best-in-class asset [2] - **MTAP Deletion Programs**: - Two clinical assets (PRMT5 and MAT2A) with opportunities for both monotherapy and combination therapy [2] - **KAT6/7 (IDE-574)**: - Entered phase 1, targeting a large patient population including breast and colorectal cancer [3] Trial Design and Expectations - **Trial Design**: - Simple randomized phase 3 comparison of darovasertib-crizotinib combination versus standard of care (checkpoint inhibitors) [15] - Control arm expected to show PFS of approximately 2-3 months based on meta-analyses [10][11] - **PFS and OS Analysis**: - The treatment arm is expected to outperform the control arm, with a significant buffer for achieving statistical significance [11][12] - Overall survival (OS) data shows a promising 21-month survival rate, with expectations for positive outcomes in the ongoing study [11][12][128] Patient Population and Disease Characteristics - **Uveal Melanoma**: - Majority of patients (over 90%) present with liver metastases, making liver-directed therapies critical [167][176] - Approximately one-third of patients have elevated LDH levels, indicating disease severity [180][181] Regulatory and Future Plans - **FDA Submission**: - Plans to file for approval based on PFS data, with OS data to be presented during the review process [136][186] - Anticipated timeline for filing and review is approximately 12 months, targeting first half of 2027 for potential approval [187] - **NCCN Guidelines**: - Plans to present data to the NCCN panel to support treatment inclusion for both HLA-A2 negative and positive patients [189] Neoadjuvant Study (OptimUM-09) - **OptimUM-09 Study**: - Focused on neoadjuvant treatment with promising results in tumor shrinkage and vision preservation [191] - Aims to change the treatment paradigm from surgical interventions to pharmacological management [195] Additional Important Information - **Safety Profile**: - Expected to be comparable to previous studies, with a focus on managing adverse events effectively [155] - Investigators are becoming more adept at handling treatment-related toxicities, which may lead to lower discontinuation rates [156] - **Data Review Process**: - The independent review of PFS is ongoing, with a target completion by the end of March 2026 [144] This summary encapsulates the key points from the IDEAYA Biosciences update, highlighting the company's focus on innovative oncology treatments, ongoing clinical trials, and strategic regulatory plans.

Summary of IDEAYA Biosciences Conference Call Company Overview - **Company**: IDEAYA Biosciences (NasdaqGS:IDYA) - **Industry**: Clinical-stage precision medicine oncology - **Key Programs**: Nine clinical programs, with a focus on uveal melanoma and other oncology indications Key Points and Arguments Upcoming Catalysts - **Darovasertib**: Lead molecule for uveal melanoma, with an upcoming top-line data release for the combination with crizotinib in metastatic uveal melanoma expected by the end of March 2026. The company has triggered the required 130 events for analysis [2][5] - **Neoadjuvant and Adjuvant Studies**: Enrollment in a neoadjuvant study is ongoing, with plans to begin an adjuvant study in Q2 2026 [3][4] Clinical Data Expectations - **Control Arm Expectations**: The control arm is expected to show a median progression-free survival (PFS) of 2-3 months and overall survival (OS) of about 13 months based on historical data [9][10] - **Darovasertib and Crizotinib Combination**: Previous data indicated a median PFS of about 7 months and OS of 21 months, significantly better than standard therapies [10][12] - **Response Rates**: Standard therapies show a response rate of around 10%, while the combination therapy has shown a response rate exceeding 30% [10] Study Design and Patient Demographics - The study focuses on HLA-A2 negative patients with metastatic uveal melanoma, comparing the combination therapy to standard care, which varies by region [8][9] - The study design includes frequent patient scans every six weeks, which may lead to earlier detection of progression compared to traditional three-month scans [15] Regulatory and Filing Timelines - **FDA Filing**: The company anticipates a six-month timeline to file for accelerated approval post-data release, with a review period of at least six months [30] - **HLA-A2 Positive Group**: Data from HLA-A2 positive patients will be presented in two chapters, with the first chapter expected to show early efficacy data [31][32] Other Pipeline Developments - **DLL3 TOPO1 ADC**: Currently in phase I studies, with initial data expected by the end of 2026. The U.S. study has launched, and early safety data is anticipated [47][48] - **MTAP Inhibitor IDE397**: Ongoing studies in combination with Trodelvy for MTAP-deleted urothelial cancer, with promising early data [59][60] - **Combination Strategies**: The company is exploring various combination therapies, including those targeting PRMT5 and CDKN2A, to enhance treatment efficacy in MTAP-deficient tumors [66][68] Market Position and Future Outlook - IDEAYA aims to set a new standard for uveal melanoma treatment, addressing a significant unmet medical need with limited existing therapies [22][14] - The company has a strong cash position of approximately $1.05 billion, providing a runway into 2030, positioning it well for upcoming clinical milestones [5] Additional Important Information - The company emphasizes the importance of data integrity and the potential for positive outcomes based on historical performance metrics [12][26] - Discussions with the FDA regarding potential label expansions and real-world data integration are ongoing, particularly for HLA-A2 positive patients [33] This summary encapsulates the key points discussed during the conference call, highlighting IDEAYA Biosciences' strategic focus on advancing its oncology pipeline and addressing critical patient needs in uveal melanoma and other cancer indications.

Core Insights - IDEAYA Biosciences has completed the targeted enrollment of 435 patients in the Phase 2/3 trial (OptimUM-02) for darovasertib in combination with crizotinib for treating first-line HLA*A2-negative metastatic uveal melanoma [1][2] - The company anticipates reporting median progression-free survival (PFS) data in Q1 2026 to support a potential accelerated approval filing in the U.S. [1][6] - Darovasertib has received FDA Breakthrough Therapy Designation and Fast Track designation for its use in metastatic uveal melanoma [4] Trial Details - The OptimUM-02 trial is a multi-arm, multi-stage, open-label study comparing the darovasertib and crizotinib combination against investigator's choice of treatment [3] - Primary endpoints include median PFS and median overall survival (OS), which will support potential accelerated and full approval filings in the U.S. [3] - Previous data from the Phase 1/2 trial (OptimUM-01) indicated a median OS of 21.1 months and median PFS of 7.0 months for the combination treatment [3] Regulatory Designations - Darovasertib has been designated as an Orphan Drug by the U.S. FDA for uveal melanoma, including metastatic cases [4] - The company is also enrolling patients in a pivotal Phase 3 trial of single-agent darovasertib in the neoadjuvant setting for primary uveal melanoma (OptimUM-10) [4] Company Overview - IDEAYA Biosciences focuses on precision medicine in oncology, aiming to develop transformative therapies for cancer through a combination of drug discovery, structural biology, and bioinformatics [5] - The company has a pipeline targeting synthetic lethality and antibody-drug conjugates for solid tumor indications [5]

Core Insights - IDEAYA Biosciences reported the first median overall survival results from their Phase 1/2 clinical trial (OptimUM-01) for darovasertib in combination with crizotinib for metastatic uveal melanoma, showing a median OS of 21.1 months [1][7] - The data will be presented at the 2025 Society for Melanoma Research Congress in Amsterdam [1] Clinical Trial Results - The trial included 44 first-line mUM patients with a median follow-up of 25 months, revealing a median progression-free survival (PFS) of 7.0 months [2] - The confirmed overall response rate (ORR) was 34% with a median duration of response (mDOR) of 9 months, and a disease control rate (DCR) of 90% [2][7] - The combination therapy demonstrated manageable tolerability, with common treatment-related adverse events including diarrhea, nausea, and fatigue [2] Comparison to Historical Data - The reported median OS of 21.1 months is significantly higher than the historical median OS of approximately 12 months for treatment-naïve patients with metastatic uveal melanoma [5][7] Future Developments - IDEAYA is conducting a registration-enabling Phase 2/3 trial (OptimUM-02) targeting HLA*A2:01-negative mUM, with median PFS data expected by the end of 2025 to early 2026 [5] - The company aims to support a potential U.S. accelerated approval filing based on the trial results [5]

Core Viewpoint - Servier and IDEAYA Biosciences have entered into an exclusive license agreement for darovasertib, a treatment for uveal melanoma, granting Servier regulatory and commercial rights outside the United States while IDEAYA retains rights in the U.S. [1][7] Company Overview - Servier is an independent international pharmaceutical group focused on delivering transformative therapies and has a strong commitment to oncology, allocating nearly 70% of its R&D budget to this field [10][12] - IDEAYA Biosciences specializes in precision medicine for oncology, focusing on the discovery and development of targeted therapies aligned with genetic drivers of cancer [14] Product Development - Darovasertib is a selective protein kinase C (PKC) inhibitor aimed at treating primary and metastatic uveal melanoma, which is a rare and aggressive form of eye cancer [1][5] - The drug has received Breakthrough Therapy Designation and Fast Track designation from the US FDA, indicating its potential as a significant treatment option [6] Financial Terms of the Agreement - IDEAYA will receive an upfront payment of $210 million, with potential additional payments of up to $320 million based on regulatory and commercial milestones, plus double-digit royalties on net sales outside the U.S. [7][8] Clinical Trials - Darovasertib is currently undergoing multiple global clinical trials, including a Phase 2/3 trial in combination with crizotinib and a Phase 3 trial evaluating it as a monotherapy [4][6] - A global Phase 3 randomized clinical trial is planned for 2026 to assess adjuvant darovasertib in primary uveal melanoma patients [4]

Core Insights - IDEAYA Biosciences announced that an abstract from its Phase 1/2 trial of darovasertib combined with crizotinib for first-line metastatic uveal melanoma has been accepted for oral presentation at the 2025 Society for Melanoma Research Congress [1][2] - The presentation will include data from over 40 patients, marking the first reported median overall survival data for the combination treatment in this indication [1][2] Company Overview - IDEAYA Biosciences is focused on precision medicine in oncology, aiming to discover, develop, and commercialize transformative cancer therapies [2] - The company integrates small-molecule drug discovery, structural biology, and bioinformatics to identify and validate translational biomarkers for developing targeted therapies [2] - IDEAYA has a pipeline that emphasizes synthetic lethality and antibody-drug conjugates for molecularly defined solid tumor indications, with a mission to enhance clinical outcomes for cancer patients [2]

Core Insights - IDEAYA Biosciences is focused on advancing precision medicines for cancer, with a strong pipeline and upcoming clinical data updates expected by year-end 2025 [1][2]. Pipeline Developments - The Phase 2/3 trial of darovasertib and crizotinib in 1L HLA-A2-negative metastatic uveal melanoma (MUM) is on track to report median progression-free survival (PFS) data by year-end 2025, which could enable a U.S. accelerated approval filing [4][5]. - Initial median overall survival data from over 40 patients in a single-arm Phase 2 trial will be presented at a medical conference in Q4 2025 [4][5]. - A randomized Phase 3 trial, OptimUM-10, will enroll approximately 520 patients in the neoadjuvant setting for primary UM, initiated in Q3 2025 [6]. Upcoming Milestones - IDEAYA will host a 10-year Anniversary R&D Day on September 8, 2025, to present multiple clinical data updates and strategic vision [2][10]. - Three investigational new drug (IND) applications are on track for submission by year-end 2025, including IDE892, IDE034, and IDE574 [4][11]. Financial Results - As of June 30, 2025, IDEAYA had approximately $991.9 million in cash, cash equivalents, and marketable securities, down from $1.05 billion as of March 31, 2025 [14][23]. - Research and development expenses for Q2 2025 totaled $74.2 million, an increase from $70.9 million in Q1 2025, primarily due to higher clinical trial expenses [15]. - The net loss for Q2 2025 was $77.5 million, compared to a net loss of $72.2 million in Q1 2025 [17].

Summary of Nuvation Bio (NUVB) FY Conference Call - May 28, 2025 Company Overview - **Company**: Nuvation Bio (NUVB) - **Focus**: Oncology, specifically targeting ROS1 positive lung cancer with the drug telotrectinib Key Industry Insights - **Upcoming Events**: Important PDUFA date for telotrectinib on June 23, 2025, and presentation at ASCO meeting regarding TRUST datasets [5][6] - **Market Dynamics**: Changes in NCCN guidelines have shifted treatment recommendations, potentially increasing the use of ROS1 agents [19][20] Core Data and Findings - **TRUST Studies**: TRUST one (China) and TRUST two (global) datasets show consistent efficacy and safety across different ethnic groups, with response rates of 89% in TKI naive patients and 52% in pretreated Asian patients [6][7][10] - **Comparative Efficacy**: Telotrectinib demonstrated a 58% reduction in risk of disease progression and a 52% reduction in risk of death compared to Roslitech, and a 52% reduction in PFS and 66% reduction in risk of death compared to crizotinib [11][12] - **Intracranial Response Rates**: 77% in naive patients and 66% in pretreated patients, highlighting the drug's effectiveness in addressing CNS metastases [16][17] Market Opportunities and Challenges - **Sales Growth**: TKI sales have increased by 20% since the new NCCN guidelines, indicating a growing market for ROS1 agents [20][21] - **Tolerability Issues**: Oktyra has faced challenges due to tolerability, with a 30% dropout rate per quarter, emphasizing the importance of good tolerability for long-term use [21][22] - **Patient Switching Dynamics**: Patients on first-generation TKIs may switch to telotrectinib if they experience intolerable side effects or disease progression [34][36] Regulatory and Approval Insights - **FDA Interactions**: Positive and responsive interactions with the FDA under breakthrough designation, with expectations for approval by the PDUFA date [37][38] - **Labeling Discussions**: Ongoing discussions regarding labeling, with no advisory committee required for approval [39][40] Future Plans and Partnerships - **European Market**: Actively seeking partnerships in Europe, with existing partnerships in Japan and China for telotrectinib [50][51] - **Pricing Strategy**: Anticipated pricing to be similar to existing competitors, with a monthly cost around $30,000 [53] Additional Research and Development - **IDH1 Mutant Product**: Ongoing phase two study for glioma, with plans for a pivotal study based on upcoming data [57][62] - **Response Rates in Glioma**: Previous ORR in low-grade glioma was 33%, significantly higher than the INDIGO study's 11% [59][60] Conclusion - **Commercial Focus**: Nuvation Bio is committed to launching telotrectinib effectively, leveraging experienced teams and focusing on patient therapy metrics as key indicators of success [47][48]

Core Insights - IDEAYA Biosciences has received FDA Breakthrough Therapy designation for darovasertib, a potential first-in-class PKC inhibitor, aimed at treating adult patients with primary uveal melanoma who are recommended for enucleation [1][2] Group 1: FDA Designation and Clinical Trials - The Breakthrough Therapy designation will facilitate the advancement of darovasertib into a potential Phase 3 registrational trial for primary uveal melanoma [2][6] - The application for BTD was supported by interim clinical data from an ongoing Phase 2 trial, showing an 82% ocular tumor shrinkage rate and a 61% eye preservation rate in patients [4][8] - A Phase 3 registrational study is targeted to be initiated in the first half of 2025, focusing on neoadjuvant darovasertib for patients eligible for enucleation or plaque brachytherapy [5][8] Group 2: Market Potential and Unmet Needs - Neoadjuvant uveal melanoma has an estimated annual incidence of approximately 12,000 patients in North America, Europe, and Australia, representing a significant unmet medical need with no FDA-approved systemic therapies currently available [5][8] - The FDA has also granted Fast Track designation for darovasertib in combination with crizotinib for metastatic uveal melanoma, with an ongoing Phase 2/3 trial [3][4] Group 3: Company Overview and Strategy - IDEAYA Biosciences focuses on precision medicine in oncology, aiming to discover and develop targeted therapeutics using molecular diagnostics [7] - The company integrates capabilities in identifying translational biomarkers with drug discovery to select patient populations most likely to benefit from its therapies [7]